Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INFU NASDAQ:INGN NASDAQ:PYPD NASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINFUInfuSystem$10.58-1.9%$7.29$4.61▼$11.04$216.11M1.82177,341 shs339,556 shsINGNInogen$8.10+1.4%$7.09$5.70▼$12.91$219.02M1.78275,182 shs215,237 shsPYPDPolyPid$3.41+1.8%$3.50$2.30▼$3.93$54.22M1.48207,217 shs97,671 shsSTIMNeuronetics$3.14-5.7%$3.76$0.52▼$5.92$207.62M1.281.23 million shs1.16 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINFUInfuSystem0.00%+9.22%+89.12%+77.89%+62.11%INGNInogen0.00%+3.63%+28.66%+25.04%-34.88%PYPDPolyPid0.00%-2.90%-1.76%+6.69%-5.63%STIMNeuronetics0.00%+4.06%-24.66%-13.73%+277.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINFUInfuSystem2.027 of 5 stars1.03.00.00.02.23.32.5INGNInogen3.9629 of 5 stars3.32.00.03.93.11.70.6PYPDPolyPid2.3976 of 5 stars3.63.00.00.02.31.70.0STIMNeuronetics2.0986 of 5 stars3.51.00.00.03.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINFUInfuSystem 4.00Strong Buy$12.5018.15% UpsideINGNInogen 2.50Moderate Buy$11.0035.80% UpsidePYPDPolyPid 3.17Buy$12.40263.64% UpsideSTIMNeuronetics 3.00Buy$7.00122.93% UpsideCurrent Analyst Ratings BreakdownLatest PYPD, STIM, INGN, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025PYPDPolyPidCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $13.008/14/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/13/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.008/6/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.007/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025PYPDPolyPidRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $9.006/17/2025PYPDPolyPidJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.006/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/9/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINFUInfuSystem$139.89M1.54$0.83 per share12.79$2.47 per share4.28INGNInogen$335.70M0.65N/AN/A$7.30 per share1.11PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ASTIMNeuronetics$74.89M2.77N/AN/A$0.57 per share5.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINFUInfuSystem$870K$0.23176.3634.13N/A1.12%2.78%1.41%N/AINGNInogen-$35.89M-$1.06N/AN/AN/A-7.58%-13.77%-8.52%11/6/2025 (Estimated)PYPDPolyPid-$29.02M-$3.83N/A∞N/AN/A-453.95%-138.92%11/12/2025 (Estimated)STIMNeuronetics-$43.71M-$1.13N/AN/AN/A-43.47%-156.36%-35.69%11/11/2025 (Estimated)Latest PYPD, STIM, INGN, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PYPDPolyPid-$0.53-$0.78-$0.25-$0.78N/AN/A8/7/2025Q2 2025INGNInogen-$0.22-$0.15+$0.07-$0.15$90.40 million$92.28 million8/5/2025Q2 2025STIMNeuronetics-$0.08-$0.15-$0.07-$0.15$36.80 million$38.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINFUInfuSystemN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINFUInfuSystem0.501.981.59INGNInogenN/A3.032.67PYPDPolyPidN/A2.282.28STIMNeuronetics1.762.021.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINFUInfuSystem71.13%INGNInogen89.94%PYPDPolyPid26.47%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipINFUInfuSystem11.40%INGNInogen1.46%PYPDPolyPid24.70%STIMNeuronetics9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINFUInfuSystem41020.43 million19.10 millionOptionableINGNInogen1,03027.04 million26.65 millionOptionablePYPDPolyPid8015.90 million11.97 millionNo DataSTIMNeuronetics18066.12 million59.65 millionOptionablePYPD, STIM, INGN, and INFU HeadlinesRecent News About These CompaniesGhisallo Capital Management LLC Buys New Shares in Neuronetics, Inc. $STIMSeptember 2 at 8:33 AM | marketbeat.comNeuronetics, Inc. (STIM) Positions as Neurohealth Leader with Adolescent BreakthroughSeptember 2 at 5:48 AM | finance.yahoo.comWalleye Capital LLC Purchases New Stake in Neuronetics, Inc. $STIMSeptember 2 at 4:25 AM | marketbeat.comHighTower Advisors LLC Reduces Holdings in Neuronetics, Inc. $STIMSeptember 1 at 3:41 AM | marketbeat.com104,597 Shares in Neuronetics, Inc. (NASDAQ:STIM) Purchased by Informed Momentum Co LLCAugust 15, 2025 | marketbeat.comCitizens Financial Group Inc. RI Invests $305,000 in Neuronetics, Inc. (NASDAQ:STIM)August 10, 2025 | marketbeat.comCanaccord Genuity Group Has Lowered Expectations for Neuronetics (NASDAQ:STIM) Stock PriceAugust 7, 2025 | marketbeat.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 6, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | msn.comNeuronetics (NASDAQ:STIM) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPSAugust 6, 2025 | marketbeat.comNeuronetics, Inc. (STIM) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comNeuronetics Reports Second Quarter 2025 Financial and Operating ResultsAugust 5, 2025 | manilatimes.netMWhat To Expect From Neuronetics Inc (STIM) Q2 2025 EarningsAugust 5, 2025 | finance.yahoo.comNeuronetics (STIM) Reports Q2 Loss, Tops Revenue EstimatesAugust 5, 2025 | zacks.comNeuronetics to Present at the Canaccord Genuity 45th Annual Growth ConferenceAugust 4, 2025 | globenewswire.comNeuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMSAugust 2, 2025 | msn.comNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsJuly 30, 2025 | globenewswire.comNeuronetics taps local industry veteran as new CFOJuly 15, 2025 | bizjournals.comNeuronetics Names Pfanstiel as CFO to Succeed FurlongJuly 15, 2025 | marketwatch.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | finance.yahoo.comNeuronetics names Steven Pfanstiel chief financial officerJuly 15, 2025 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?By Ryan Hasson | August 9, 2025PYPD, STIM, INGN, and INFU Company DescriptionsInfuSystem NYSE:INFU$10.58 -0.20 (-1.86%) Closing price 04:00 PM EasternExtended Trading$10.58 +0.01 (+0.05%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Inogen NASDAQ:INGN$8.10 +0.11 (+1.38%) Closing price 04:00 PM EasternExtended Trading$8.10 0.00 (-0.06%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.PolyPid NASDAQ:PYPD$3.41 +0.06 (+1.79%) Closing price 04:00 PM EasternExtended Trading$3.38 -0.04 (-1.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Neuronetics NASDAQ:STIM$3.14 -0.19 (-5.71%) Closing price 04:00 PM EasternExtended Trading$3.20 +0.06 (+2.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
